|
SPIRE1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.55111512312578E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.48240333739136E-11 |
| Normal-vs-Stage2 |
9.73069999999909E-05 |
| Normal-vs-Stage3 |
9.59790003030037E-09 |
| Normal-vs-Stage4 |
1.68013999999328E-05 |
| Stage1-vs-Stage2 |
1.520040E-01 |
| Stage1-vs-Stage3 |
5.432800E-01 |
| Stage1-vs-Stage4 |
2.191200E-01 |
| Stage2-vs-Stage3 |
2.947400E-01 |
| Stage2-vs-Stage4 |
6.703400E-01 |
| Stage3-vs-Stage4 |
4.619000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66056057793185E-12 |
| Normal-vs-AfricanAmerican |
1.173860E-02 |
| Normal-vs-Asian |
1.341560E-03 |
| Caucasian-vs-AfricanAmerican |
5.600400E-01 |
| Caucasian-vs-Asian |
6.747000E-01 |
| AfricanAmerican-vs-Asian |
8.290400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.89569999884543E-08 |
| Normal-vs-Female |
4.55191440096314E-15 |
| Male-vs-Female |
3.552600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.37500000274571E-09 |
| Normal-vs-Age(41-60Yrs) |
4.43060033106235E-10 |
| Normal-vs-Age(61-80Yrs) |
5.14590003941606E-09 |
| Normal-vs-Age(81-100Yrs) |
3.790400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.494400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.609200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.435300E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.294200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.760900E-03 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.185200E-04 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.531380E-01 |
| Classical-VS-Follicular |
8.326800E-01 |
| Classical-VS-Other |
1.486570E-01 |
| Classical-VS-Normal |
6.55031584528842E-15 |
| Tall-VS-Follicular |
2.167600E-01 |
| Tall-VS-Other |
7.069800E-02 |
| Tall-VS-Normal |
9.52830000455762E-08 |
| Follicular-VS-Other |
2.540200E-01 |
| Follicular-VS-Normal |
7.92790000000432E-05 |
| Other-VS-Normal |
2.921900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.45840015011822E-10 |
| Normal-vs-N1 |
4.617300E-04 |
| N0-vs-N1 |
7.562400E-01 |
|
|
